Subscribe
Subscribe
Picture of V-Bio Ventures

V-Bio Ventures

We are a life sciences fund investing throughout Europe in start-up and early-stage companies with high growth potential. Our articles cover investment-related topics in life sciences, including innovation trends, the latest business themes and exciting updates on our portfolio companies.
Picture of V-Bio Ventures

V-Bio Ventures

We are a life sciences fund investing throughout Europe in start-up and early-stage companies with high growth potential. Our articles cover investment-related topics in life sciences, including innovation trends, the latest business themes and exciting updates on our portfolio companies.

We need more food and agtech start-ups – and we need them now!

How are we going to feed an expected 10 billion people by 2050 in a sustainable way? It is a daunting task. Our climate is changing, and a combination of environmental and economic factors are already resulting in widespread food shortages. There is no simple solution to this problem, but innovation in the food and agtech sector will help alleviate the burden. To make this possible, stakeholders – including researchers, entrepreneurs, investors, and governments – need to make agrifood innovation a priority immediately.

V-Bio Ventures leads Sibylla Biotech’s EUR 23 million Series A to advance a novel therapeutic approach for undruggable diseases

VC opportunities for impact in the face of climate disaster

Venture capitalists have a vital role to play in guiding our planet’s future. By investing in technological advances that remediate environmental ruination, enable adaptation to new conditions, and heal challenging diseases, VC funds can help improve the world while also benefiting their bottom line. But there is an even bolder approach available to VCs who really want to do good: influencing governments by earmarking funds for advocacy groups.

V-Bio Ventures portfolio company Biodol Therapeutics nominates its first preclinical candidate as a next-generation therapy for neuropathic pain

KU Leuven spin-off AstriVax raises € 30 million to build vaccine platform

Augustine Therapeutics: time to reverse nerve damage in patients undergoing chemotherapy or with Charcot-Marie-Tooth disease

Augustine Therapeutics is a VIB and KU Leuven spin-off developing innovative therapies for peripheral and central nervous system disorders. The company initially focused on treating Charcot-Marie-Tooth disease, and recently added a major indication to their lead program after finding strong evidence that their drug candidate can also reverse nerve damage caused by chemotherapy. Augustine Therapeutics aims to initiate clinical trials by 2024.

Is the dot-com bubble bursting all over again?

The stock market value of biotech companies has been crashing lately, bitterly reminiscent of the dot-com bubble burst in the early 2000s. Should investors and startups be panicking? Or might there be a silver lining to this stormy cloud?

Dualyx: restoring the body’s balance in autoimmune diseases

Belgian start-up Dualyx is developing a novel approach with the potential to treat a wide range of autoimmune disorders. The method uses llama-derived antibodies to flip a master switch and create regulatory T cells, which help restore order to overzealous immune systems.

Drug development trends: from common to orphan indications… and back again?

Over the past few decades, pharma has gradually shifted its target patient focus for newly launched drugs from large to niche populations. What has caused this trend, and is the pendulum of drug development swinging back again?

V-Bio Ventures raises EUR 110 million for its second fund and expands team

Ghent, Belgium, 31 March 2022 – V-Bio Ventures announced the final closing of its second fund, V-Bio Fund 2, having raised EUR 110 million euro and exceeding its target of EUR 100 million.

Antimicrobial Resistance – the hidden killer we’re ignoring

Antimicrobial Resistance has become an enormous challenge for global health, yet remains largely ignored by companies. As this deadly race worsens, we urgently need to address the huge mismatch between the need and incentive for developing new antimicrobial drugs.

V-Bio Ventures’ Portfolio Company Precirix raises EUR 80 million in Series B to advance its pipeline of precision radiopharmaceuticals

V-Bio Ventures’ Portfolio Company Syndesi Therapeutics Acquired by AbbVie to Strengthen its Neuroscience Portfolio

When should a biotech hire a CFO?

Many argue that young companies have little need for a Chief Financial Officer (CFO). They would say that CFOs are unnecessary and costly add-ons early on when a business’ financial needs can be satisfied through outsourcing or by a more junior member of staff. However a CFO brings a deeper and more strategic financial perspective which can help a company outgrow the competition. So, is delaying CFO recruitment a sensible budgetary decision or an expensive mistake?

V-Bio Ventures raises additional capital to support young biotech companies

Ghent, Belgium, 27 January 2022 - V-Bio Ventures, a venture capital company that focuses specifically on the segment of young pioneering biotech companies, has increased the capital of its second fund V-Bio Fund 2 to 96 million euros. The fundraising will continue for several months, and the fund managers expect the target of EUR 100 million will be achieved.